2. Academic Validation
  3. Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals

Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals

  • Antimicrob Agents Chemother. 1996 Nov;40(11):2664-8. doi: 10.1128/AAC.40.11.2664.
A M Been-Tiktak 1,  I Williams,  H M Vrehen,  J Richens,  D Aldam,  A M van Loon,  C Loveday,  C A Boucher,  P Ward,  I V Weller,  J C Borleffs
Affiliations

Affiliation

  • 1 Department of Internal Medicine, University Hospital Utrecht, The Netherlands.
PMID: 8913487 DOI: 10.1128/AAC.40.11.2664
Abstract

Atevirdine is a nonnucleoside Reverse Transcriptase Inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infected patients with CD4+ cell counts of between 200 and 750 cells per mm3. Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4+ cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15379
    98.69%, HIV-1 Reverse Transcriptase Inhibitor
    HIV